Tanimoto Shuji, Fukumori Tomoharu, El-Moula Gad, Shiirevnyamba Avirmed, Kinouchi Shinichiro, Koizumi Takahiro, Nakanishi Ryoichi, Yamamoto Yasuyo, Taue Ryuichi, Yamaguchi Kunihisa, Nakatsuji Hiroyoshi, Kishimoto Tomoteru, Izaki Hirofumi, Oka Natsuo, Takahashi Masayuki, Kanayama Hiro-Omi
Department of Urology, Takamatsu Red Cross Hospital, Tokushima, Japan.
J Med Invest. 2008 Feb;55(1-2):106-11. doi: 10.2152/jmi.55.106.
No adequate serum predictive biomarker currently exists, which can identify the activity of renal cell carcinoma (RCC). We investigate the association of serum hepatocyte growth factor (HGF) and serum vascular endothelial growth factor (VEGF) levels with clinicopathologic parameters in untreated clear cell RCC patients. We measured serum levels of HGF and VEGF in 45 patients with untreated clear cell RCC and 45 healthy controls using an enzyme-linked immunosorbent assay (ELISA). Patients with clear cell RCC had significantly higher serum HGF and VEGF concentrations than healthy subjects: median, 1070.7 versus 728.3 pg/ml (p<0.0001) for HGF; and median, 397.5 versus 245.6 pg/ml (p=0.0003) for VEGF. We found a significant correlation between serum level of HGF and clinical stage and tumor grade. Survival of patients with high serum HGF (>1150 pg/ml) was significantly reduced compared to patients with low serum HGF concentrations (p=0.0044). In patients with nuclear grade 2 or high stage RCC, the higher serum HGF group exhibited significantly lower cause-specific survival (p=0.0087 and p< 0.05, respectively). No significant difference was observed between serum VEGF levels and cause-specific survival rate. Serum HGF might be a diagnostic and prognostic indicator in clear cell RCC, especially for patients with grade 2 or high stage RCC.
目前尚无足够的血清预测生物标志物可用于识别肾细胞癌（RCC）的活性。我们研究了未经治疗的透明细胞RCC患者血清肝细胞生长因子（HGF）和血清血管内皮生长因子（VEGF）水平与临床病理参数之间的关联。我们使用酶联免疫吸附测定（ELISA）法测量了45例未经治疗的透明细胞RCC患者和45例健康对照者的血清HGF和VEGF水平。透明细胞RCC患者的血清HGF和VEGF浓度显著高于健康受试者：HGF的中位数分别为1070.7 pg/ml和728.3 pg/ml（p<0.0001）；VEGF的中位数分别为397.5 pg/ml和245.6 pg/ml（p=0.0003）。我们发现血清HGF水平与临床分期和肿瘤分级之间存在显著相关性。血清HGF水平高（>1150 pg/ml）的患者的生存率与血清HGF浓度低的患者相比显著降低（p=0.0044）。在核分级为2级或高分期RCC患者中，血清HGF水平较高的组的病因特异性生存率显著较低（分别为p=0.0087和p<0.０５）。血清VEGF水平与病因特异性生存率之间未观察到显著差异。血清HGF可能是透明细胞RCC的诊断和预后指标，尤其是对于2级或高分期RCC患者。
